News provided by
Share this article
LifeSphere Safety increases its customer footprint, further solidifying its safety market leadership position. MIAMI, Oct. 27, 2022 /PRNewswire/ -- ArisGlobal , the leading provider of life sciences software designed to automate core drug development functions with its end-to-end technology platform LifeSphere®, has expanded the global adoption of LifeSphere Safety by adding PegBio Co., Ltd.  to its customer roster. PegBio selected LifeSphere MultiVigilance, a flagship product within the market-leading safety product line, to transition its pharmacovigilance from Contract Research Organization (CRO) services to in-house practices with the leading pharmacovigilance software. ArisGlobal Logo (PRNewsfoto/ArisGlobal)
"At PegBio, we are laser-focused on fighting chronic disease with safe, novel, and effective therapies, and we hold patient safety in the highest regard," shares Ruifang Liang, Senior VP of PegBio. "We believe that by moving our pharmacovigilance strategy to ArisGlobal's LifeSphere, we will be able to not only meet, but exceed, safety expectations and efficiencies." LifeSphere Safety will enable PegBio, a biopharma specialized in the development of diabetes and obesity therapies, to bring operations in-house and control drug development through customized service, authority connection, cloud service, and bilingual language translation capabilities. "LifeSphere Safety is several years ahead of any other safety solution on the market, and we are thrilled to welcome PegBio to our customer roster as an innovative organization working towards chronic disease therapies," says Ye Zha, Head of Country, China, at ArisGlobal. "With the increased prioritization of safety, in-house pharmacovigilance has become essential. LifeSphere MultiVigilance will provide a critical level of support and enhance PegBio's ability to safely and efficiently develop and deliver drugs in this key global market and beyond." By adding PegBio to its portfolio, ArisGlobal continues growing its commitment to pharmacovigilance and the safety of global drug development along with its ever-expanding footprint within China's life sciences sector. For more information about ArisGlobal and the LifeSphere Safety platform, please visit arisglobal.com . About PegBio
Founded in 2008, Pegbio Co., Ltd. is a biomedical enterprise committed to the research and development and production of innovative drugs in the field of chronic disease treatment, which has developed a series of advantageous products, including polypeptide drugs, protein drugs, and small molecule drugs through independent research and development. About LifeSphere
LifeSphere® is the trusted partner for global pharmaceutical and biotechnology companies, health authorities, and contract research organizations. Helping accelerate product development, organize clinical trials, manage compliance, and streamline collaboration across teams, LifeSphere empowers safer, faster life science breakthroughs. As the flagship platform of ArisGlobal, LifeSphere is a market-leading solution built on 40 years of industry partnership and continues to evolve in collaboration with hundreds of trusted customers worldwide. For more information visit lifesphere.arisglobal.com. About ArisGlobal
ArisGlobal is led by passionate individuals who support life sciences leaders in developing and monitoring breakthrough medicines and therapies. With more than 35 years of expertise in the life sciences industry, ArisGlobal develops technology products within the platform LifeSphere to power pharmaceutical and biotech research and development. Building on our commitment to corporate social responsibility and sustainability initiatives, we give back to the communities where we live and work – in the U.S, Europe, India, Japan, and China. For more information visit https://www.arisglobal.com/ . SOURCE ArisGlobal

09:00 EDT
China's PegBio Selects LifeSphere by ArisGlobal for Safety Case Processing

News provided by
Share this article
Share this article
The Global GLP-1 Receptor Agonist Market size was estimated at USD 3,632.28 million in 2021, USD 4,016.94 million in 2022, and is projected to grow at a Compound Annual Growth Rate (CAGR) of 10.84% to reach USD 6,737.14 million by 2027. Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period. FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the GLP-1 Receptor Agonist Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape. Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits. The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global GLP-1 Receptor Agonist Market? 2. What are the inhibiting factors and impact of COVID-19 shaping the Global GLP-1 Receptor Agonist Market during the forecast period? 3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global GLP-1 Receptor Agonist Market? 4. What is the competitive strategic window for opportunities in the Global GLP-1 Receptor Agonist Market? 5. What are the technology trends and regulatory frameworks in the Global GLP-1 Receptor Agonist Market? 6. What is the market share of the leading vendors in the Global GLP-1 Receptor Agonist Market? 7. What modes and strategic moves are considered suitable for entering the Global GLP-1 Receptor Agonist Market? Key Topics Covered:

Global GLP-1 Receptor Agonist Market Research Report to 2027 - Featuring Novo Nordisk, PegBio and Sanofi Among Others

15:15 EDT
Global GLP-1 Receptor Agonist Market Research Report to 2027 - Featuring Novo Nordisk, PegBio and Sanofi Among Others

Chinese biopharma firm developing diabetes drugs raises $122 million in lead-up to IPO
Business & Technology
China has the world’s largest population of diabetics. Pegbio is raising boatloads of money to develop drugs to treat diabetes and other chronic conditions. Close post dialog window
Pegbio, a biopharmaceutical company specializing in developing drugs to treat chronic diseases, especially diabetes and obesity, announced  last week that it has raised around 800 million yuan ($122 million) in a pre-IPO round. No valuation was mentioned. The round was led by Jack Ma’s Yunfeng Capital, Yingke PE, and life-science-specialized TF Capital, and joined by Qianhai FoF, Zhongxin Huihai Investment Fund Management, Yuanfeng Capital, and the existing investor YuanBio Venture Capital. Pegbio said it has begun preparation work to go public on Shanghai’s Nasdaq-style STAR market. Pegbio was founded by Chinese-American scientist Michael Xu (徐敏 Xú Mǐn), who participated in Beijing’s Thousand Talent Plan, a Chinese science and technology recruitment program that has been facing  intensive scrutiny from Washington. Xu was named a “State Specially Recruited Expert” under the Thousand Talent Plan for his entrepreneurship, according to Pegbio’s website . Xu earned his Ph.D. in biochemistry and his M.B.A. from Columbia University in 1996, after an undergraduate degree from Xiangya School of Medicine at Central South University. After moving back to China in 1997, Xu worked for multiple American and Chinese pharmaceutical companies before founding his first biotechnology company in 2001. Xu founded Pegbio in 2008 to focus on the research and development (R&D) of macromolecular drugs to fight chronic diseases like type 2 diabetes, non-alcoholic fatty liver, gout, constipation, and cardiovascular illnesses. Pegbio will use the latest funding to promote its drugs’ global clinical trials, support drug R&D, and introduce licensed drugs from overseas to the Chinese market. Pegbio’s flagship drug candidate PB-119, which treats type 2 diabetes, has begun the Phase 3 clinical trial in China after completing the first two phases in both the U.S. and China, according to the company’s announcement last month . Pegbio is also working with American global pharmaceutical giant Pfizer to develop a new type of drug for diabetes treatment — PB-201. As part of the partnership, Pegbio began  the drug’s Phase 1 clinical trials in Beijing last August. China is witnessing a surge in diabetes patients. Nearly 130 million Chinese are suffering from diabetes, making China the country with the highest number of diabetics in the world, according to Xinhua . Han Chinese also develop diabetes at lower levels of excess weight , at least when compared with Caucasian populations. 12.8% of adults in China now have diabetes, compared with less than 1%  in 1980. The trend has raised the alarm for health authorities, who began to invest aggressively in the procurement  and development of diabetes drugs. In 2017, Pegbio’s ongoing R&D of PB-119 was titled  a “Major Science and Technology Project for New Drug Creation” under Beijing’s 13th Five-Year Plan, and received more than 15 million yuan ($2.3 million) of special funding from China’s National Health Commission. Luz Ding is a freelance journalist based in Washington, D.C., covering China, U.S.-China relations, and the Korean Peninsula. She previously worked as a researcher for the New York Times in Beijing and a reporter for Caixin Media. Read more
Suggested for you

Chinese biopharma firm developing diabetes drugs raises $122 million in lead-up to IPO

ArisGlobal is a company focused on providing cloud-based solutions for the life sciences sector. The company offers an end-to-end drug development platform that automates core functions of the drug development lifecycle, including safety, clinical, regulatory, and medical affairs. ArisGlobal primarily serves the life sciences industry, including pharmaceutical and biotech companies, contract research organizations, and regulatory agencies. It was founded in 1987 and is based in Miami, Florida.

ArisGlobal

As the flagship platform of ArisGlobal , LifeSphere Safety is a market-leading solution built on 40 years of industry partnership and continues to evolve in collaboration with hundreds of trusted customers worldwide .

Pfizer (NYSE: PFE) offers a diversified health care portfolio including human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and consumer products. It works across various markets to promote wellness, prevention, treatments, and cures that challenge feared diseases. The company collaborates with health care providers, governments, and local communities to support and expand access to reliable, affordable health care around the world. The company was founded in 1849 and is based in New York, New York.

Pfizer

Series A - II

Series F

PegBio is a bio-pharmaceutical company engaging in manufacturing polyethylene glycol (PEG) and development of PEGylation technology leading to PEGylated drugs as putative new molecule entities (pNMEs) in China.

Name	Michael Xu
Work History
Title	Chief Executive Officer
Status	Current

Wells Fargo Success Story

Professional Services

Platform Overview

PegBio

Executives

PegBio Management Team

1 Team Member